1.Irreversible Electroporation in Patients with Pancreatic Cancer :Angel and Devil
Jiyoung KEUM ; Hee Seung LEE ; Huapyong KANG ; Jung Hyun JO ; Moon Jae CHUNG ; Jeong Youp PARK ; Seung Woo PARK ; Si Young SONG ; Seungmin BANG
Journal of Digestive Cancer Report 2019;7(1):26-30
Pancreatic cancer has a very poor prognosis. Complete surgical resection remains the only current curative treatment. Locally advanced pancreatic cancer (LAPC) is considered as unresectable because of involvement of celiac and/or mesenteric vessels. The treatment of LAPC is a challenge. Current guidelines suggest systemic therapy. However, the majority of patients will never experience conversion to surgical resection. Thus, in these patients, ablation is an alternative therapy for local control, which causes local destruction while ideally avoiding injury to surrounding healthy tissue. Irreversible electroporation (IRE) is an energy delivery system, effective in ablating tumors by inducing irreversible membrane destruction of cells. IRE demonstrated to be safe in previous studies. However, it is not free from complications, even serious. Here, we reported two cases of the IRE in LAPC patients.
Electroporation
;
Humans
;
Membranes
;
Pancreatic Neoplasms
;
Prognosis
2.Extraordinary Response of Metastatic Pancreatic Cancer to Chemotherapy
Dong Woo SHIN ; Jinkook KIM ; Jong Chan LEE ; Jaihwan KIM ; Jin Hyeok HWANG
Journal of Digestive Cancer Report 2019;7(1):22-25
A 58-year-old woman presented with right flank and back pain for one month. After undergoing an abdominal computed tomography (CT), she was referred to our hospital. The abdominal CT showed a hypodense pancreatic tail mass with multiple retroperitoneal lymph node metastases. Positron emission tomography-computed tomography (PET-CT) scan showed high 18F-FDG uptake in pancreatic tumor and enlarged lymph nodes. Endoscopic ultrasound fine needle aspiration (EUS-FNA) revealed adenocarcinoma, which stained strongly in hENT1 (human equilibrative nucleoside transporter 1) on immunohistochemistry. She received gemcitabine 1,000 mg/m² + nanoparticle albumin-bound paclitaxel 125 mg/m² as a palliative chemotherapy. Follow-up abdominal CT and PET-CT after 4 cycles of chemotherapy showed that both pancreatic mass and the metastatic retroperitoneal lymph nodes were nearly disappeared. We report a case of 58-year-old female with metastatic pancreatic cancer who had a dramatic response to palliative chemotherapy (gemcitabine plus nanoparticle albumin-bound paclitaxel).
Adenocarcinoma
;
Albumin-Bound Paclitaxel
;
Back Pain
;
Biopsy, Fine-Needle
;
Drug Therapy
;
Electrons
;
Female
;
Fluorodeoxyglucose F18
;
Follow-Up Studies
;
Humans
;
Immunohistochemistry
;
Lymph Nodes
;
Middle Aged
;
Nanoparticles
;
Neoplasm Metastasis
;
Nucleoside Transport Proteins
;
Pancreatic Neoplasms
;
Tail
;
Tomography, X-Ray Computed
;
Ultrasonography
3.A Case of 47-Years-Old Female with Obstructive Jaundice and Weight Loss
Pil Gyu PARK ; Huapyong KANG ; Moon Jae CHUNG ; Jeong Youp PARK ; Seungmin BANG ; Seung Woo PARK ; Si Young SONG ; Hee Seung LEE
Journal of Digestive Cancer Report 2019;7(1):18-21
Serine protease inhibitor Kazal-type 1 (SPINK1) is a gene expressed from pancreatic acinar cell which its mutation is known to be associated with chronic pancreatitis (CP) and pancreatic cancer. We report a case of a 47-years-old female with nausea and weight loss with yellow discoloration of skin. Initial imaging and endoscopic study led us to an impression of chronic pancreatitis with pancreatic cancer with common bile-duct dilation. Biopsy result was confirmed with pancreatic adenocarcinoma and additional imaging revealed lymph node and bone metastasis. Our genetic analysis revealed 194+2T>C mutation of SPINK1. Biliary obstruction was successfully decompressed by stent insertion and underwent chemotherapy and radiotherapy. Although there is accumulating evidence of association between SPINK1 mutation and CP, the relationship between SPINK1 mutation and pancreatic cancer in CP patient is an emerging concept. Genetic analysis should be considered in patients with young age especially when diagnosed with both CP and pancreatic cancer.
Acinar Cells
;
Adenocarcinoma
;
Biopsy
;
Drug Therapy
;
Female
;
Genes, vif
;
Humans
;
Jaundice, Obstructive
;
Lymph Nodes
;
Nausea
;
Neoplasm Metastasis
;
Pancreatic Neoplasms
;
Pancreatitis, Chronic
;
Radiotherapy
;
Serine Proteases
;
Skin
;
Stents
;
Weight Loss
4.Clinicopathologic Implication of New AJCC 8(th) Staging Classification in the Stomach Cancer
Journal of Digestive Cancer Report 2019;7(1):13-17
Stomach cancer is the fifth most common malignancy in the world. The incidence of stomach cancer is declining worldwide, however, gastric cancer still remains the third most common cause of cancer death. The tumor, node, and metastasis (TNM) staging system has been frequently used as a method for cancer staging system and the most important reference in cancer treatment. In 2016, the classification of gastric cancer TNM staging was revised in the 8(th) American Joint Committee on Cancer (AJCC) edition. There are several modifications in stomach cancer staging in this edition compared to the 7(th) edition. First, the anatomical boundary between esophagus and stomach has been revised, therefore the definition of stomach cancer and esophageal cancer has refined. Second, N3 is separated into N3a and N3b in pathological classification. Patients with N3a and N3b revealed distinct prognosis in stomach cancer, and these results brought changes in pathological staging. Several large retrospective studies were conducted to compare staging between the 7(th) and 8(th) AJCC editions including prognostic value, stage grouping homogeneity, discriminatory ability, and monotonicity of gradients globally. The main objective of this review is to evaluate the clinical and pathological implications of AJCC 8(th) staging classification in the stomach cancer.
Classification
;
Esophageal Neoplasms
;
Esophagus
;
Humans
;
Incidence
;
Joints
;
Methods
;
Neoplasm Metastasis
;
Neoplasm Staging
;
Prognosis
;
Retrospective Studies
;
Stomach Neoplasms
;
Stomach
5.Various Classification of Gastric Adenocarcinoma
Hee Seok MOON ; Hyun Yong JEONG
Journal of Digestive Cancer Report 2019;7(1):8-12
Despite its declining incidence, gastric cancer is globally, still, the third most common cause of cancer-related mortality. Gastric cancer is a heterogeneous disease with diverse pathogenesis and molecular backgrounds. Therefore several systems have been proposed to aid in the classification of gastric adenocarcinoma based on the macroscopic, microscopic and anatomical features of the tumor. However, these classifications did not reflect the pathogenesis of the disease. Recently, genomic analysis has identified several subtypes of gastric adenocarcinoma and a detailed understanding of the molecular biology behind the neoplastic phenotype is possible to develop of more effective therapies. We will describe the existing various classification of gastric cancer and the recently introduced molecular biology and immunological classification.
Adenocarcinoma
;
Classification
;
Incidence
;
Molecular Biology
;
Mortality
;
Phenotype
;
Stomach Neoplasms
6.Adjuvant Therapy of Pancreatic Cancer
Journal of Digestive Cancer Report 2019;7(1):5-7
Pancreatic cancer is a lethal disease since curative resection is available in only 20% of patients at the initial diagnosis. Even after radical resection of the cancer, most patients experience recurrence. Therefore, many clinical trials have been attempted to prevent recurrence of pancreatic cancer. The key clinical studies about adjuvant therapy of pancreatic cancer and currently available regimens in Korea will be reviewed concisely according to the chemotherapy, radiation therapy, or both.
Diagnosis
;
Drug Therapy
;
Humans
;
Korea
;
Pancreatic Neoplasms
;
Recurrence
7.Chemotherapy for Patients with Colorectal Cancer - When and How?
Journal of Digestive Cancer Report 2019;7(1):1-4
It is important to choose the appropriate treatment option for patients with colorectal cancer (CRC), because it could affect the prognosis of patients. Chemotherapy is effective in prolonging survival and time to progression in patients with advanced CRC. Adjuvant chemotherapy have been reported to reduce the recurrence rate of colorectal cancer by 30% in patients with stage 3 or high risk of stage 2 CRC. Although palliative chemotherapy does not offer long-term benefits, as life expectancy remains below 12 months in most of those receiving treatment, recent developments in the treatment including target agents and immunotherapy have improved the median overall survival time in patients with metastatic CRC by up to 30 months. Chemotherapy for patients with CRC is classified into neoadjuvant, adjuvant, and palliative therapy according to the status of patients. In this review, I summarized the chemotherapy for patients with CRC, which applying in clinical practice.
Chemotherapy, Adjuvant
;
Colorectal Neoplasms
;
Drug Therapy
;
Humans
;
Immunotherapy
;
Life Expectancy
;
Palliative Care
;
Prognosis
;
Recurrence
8.Two Cases of Unresectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgical Resection
Gunn HUH ; Jung Won CHUN ; Min Su YOU ; Woo Hyun PAIK ; Sang Hyub LEE ; Yong Tae KIM ; Ji Kon RYU
Journal of Digestive Cancer Report 2019;7(2):61-64
We report two cases of patients with unresectable pancreatic cancer treated with neoadjuvant chemotherapy and surgical resection. In the first case, main mass was located at the neck of the pancreas, encasing superior mesenteric artery and peritoneal seeding was suspected. In the second case, main mass was located at the body of pancreas and superior mesenteric artery was encased. Both patients received FOLFIRINOX chemotherapy regimen, consisting of 5-FU, folinic acid, irinotecan and oxaliplatin. In both cases, tumor size decreased and vascular involvement regressed in response to chemotherapy. After subsequent chemoradiation therapy, both patients underwent surgical resection with negative resection margin. The pathological stages were ypT1cN0 and ypT1aN0, respectively. Both patients received postoperative adjuvant chemotherapy with 6 cycles of 5-FU/folinic acid and remained without evidence of disease for more than 6 months after the surgery.
9.Salvage Endoscopic Resection for Residual Lesion after Definitive Chemoradiotherapy in Esophageal Cancer
Seong Jung KIM ; Ran HONG ; Jun LEE
Journal of Digestive Cancer Report 2019;7(2):57-60
Definitive chemoradiotherapy (CRT) with its significant efficacy and safety in esophageal cancer is reserved for patients with unresectable tumor or those who decline surgery. However, the incidence of locoregional failure or recurrence after definitive CRT remains high. Although esophagectomy is the standard treatment for locoregional failure or recurrence, this approach is associated with high mortality and morbidity. A 56-year-old man diagnosed with esophageal squamous cell carcinoma who refused to undergo surgery received definitive CRT. An endoscopy for response assessment performed after 2 months revealed a residual lesion, which was completely resected by salvage endoscopic submucosal dissection. To the best of our knowledge, endoscopic resection in locoregional failure or recurrence after definitive CRT is very rarely reported, and there are no guidelines or consensus to date. Here, we report a case of successful salvage endoscopic resection of residual lesion after definitive CRT.
10.Cholelithiasis as a Risk Factor for Gallbladder Cancer
Dong Jun OH ; Dong Kee JANG ; Jun Kyu LEE
Journal of Digestive Cancer Report 2019;7(2):51-56
Although the incidence of gallbladder cancer is relatively low, Korea is one of the countries with the highest incidences of gallbladder cancer in the world. Gallbladder cancer is also often diagnosed in an advanced state, and has poor prognosis. A gallstone is one of the major risk factors for gallbladder cancer and a majority of epidemiological studies support correlation between cholelithiasis and gallbladder cancer. Clear mechanism, however, regarding how gallstones cause gallbladder cancer is not known. In this article, results of studies about the relationship between gallstone and gallbladder cancer were thoroughly reviewed. Also, it was discussed whether prophylactic cholecystectomy is necessary to prevent gallbladder cancer in asymptomatic gallstone patients without other risk factors such as a gallbladder polyp or porcelain gallbladder.